Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Copper diethyldithiocarbamate is a small molecule copper complex formed by chelation of copper(II) ions with diethyldithiocarbamate ligands. It is the active anticancer agent generated from disulfiram in the presence of copper, showing cytotoxic activity against tumor cells via inhibition of the proteasome, specifically targeting the 19S lid of the proteasome. Therapeutically, it is primarily being investigated for anticancer uses, including glioma and leukemia models, where liposomal formulations have increased efficacy and bioavailability in animal studies. Its pharmacological activity is distinct from its precursor disulfiram, and the compound is poorly water-soluble, presenting formulation challenges for therapeutic use[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on copper diethyldithiocarbamate.